Mariano A Giorgi

Summary

Publications

  1. pmc Rivaroxaban in atrial fibrillation
    Mariano A Giorgi
    Cardiology Service, Centro de Educación Médica e Investigaciones Clínicas Norberto Quirno, Buenos Aires, Argentina
    Vasc Health Risk Manag 8:525-31. 2012
  2. ncbi request reprint QT interval prolongation: preclinical and clinical testing arrhythmogenesis in drugs and regulatory implications
    Mariano A Giorgi
    Department of Cardiology, Instituto FLENI, and Institute of Epidemiological Research, National Academy of Medicine, Buenos Aires, Argentina
    Curr Drug Saf 5:54-7. 2010
  3. doi request reprint Nonresponders to clopidogrel: pharmacokinetics and interactions involved
    Mariano A Giorgi
    Department of Cardiology and Cardiovascular Surgery, FLENI, Montañeses 2325 1428, Buenos Aires, Argentina
    Expert Opin Pharmacother 11:2391-403. 2010
  4. doi request reprint Beyond efficacy: pharmacokinetic differences between clopidogrel, prasugrel and ticagrelor
    Mariano A Giorgi
    Department of Cardiology and Cardiovascular Surgery, Instituto FLENI, Montañes, Buenos Aires, Argentina
    Expert Opin Pharmacother 12:1285-95. 2011
  5. doi request reprint Changing anticoagulant paradigms for atrial fibrillation: dabigatran, apixaban and rivaroxaban
    Mariano A Giorgi
    Department of Cardiology and Cardiovascular Surgery, FLENI, Montañeses 2325 1428, Buenos Aires, Argentina
    Expert Opin Pharmacother 12:567-77. 2011
  6. doi request reprint Pharmacogenomics and adverse drug reactions: the case of statins
    Mariano A Giorgi
    Department of Cardiology and Cardiovascular Surgery, Montañeses 2325 1428, FLENI, Buenos Aires, Argentina
    Expert Opin Pharmacother 12:1499-509. 2011

Collaborators

Detail Information

Publications6

  1. pmc Rivaroxaban in atrial fibrillation
    Mariano A Giorgi
    Cardiology Service, Centro de Educación Médica e Investigaciones Clínicas Norberto Quirno, Buenos Aires, Argentina
    Vasc Health Risk Manag 8:525-31. 2012
    ..Rivaroxaban is an attractive alternative, but the true picture of this novel compound in atrial fibrillation will only become available with more widespread use...
  2. ncbi request reprint QT interval prolongation: preclinical and clinical testing arrhythmogenesis in drugs and regulatory implications
    Mariano A Giorgi
    Department of Cardiology, Instituto FLENI, and Institute of Epidemiological Research, National Academy of Medicine, Buenos Aires, Argentina
    Curr Drug Saf 5:54-7. 2010
    ....
  3. doi request reprint Nonresponders to clopidogrel: pharmacokinetics and interactions involved
    Mariano A Giorgi
    Department of Cardiology and Cardiovascular Surgery, FLENI, Montañeses 2325 1428, Buenos Aires, Argentina
    Expert Opin Pharmacother 11:2391-403. 2010
    ..g., between proton pump inhibitors (PPIs) and clopidogrel) are both associated with decreased clopidogrel efficacy. Despite all PPIs being potent inhibitors of CYP2C19, evidence about their clinical impact is controversial...
  4. doi request reprint Beyond efficacy: pharmacokinetic differences between clopidogrel, prasugrel and ticagrelor
    Mariano A Giorgi
    Department of Cardiology and Cardiovascular Surgery, Instituto FLENI, Montañes, Buenos Aires, Argentina
    Expert Opin Pharmacother 12:1285-95. 2011
    ..This has led to the development of other P2Y12 receptor inhibitors, such as prasugrel and ticagrelor, with different pharmacokinetic characteristics that influence their pharmacodynamics...
  5. doi request reprint Changing anticoagulant paradigms for atrial fibrillation: dabigatran, apixaban and rivaroxaban
    Mariano A Giorgi
    Department of Cardiology and Cardiovascular Surgery, FLENI, Montañeses 2325 1428, Buenos Aires, Argentina
    Expert Opin Pharmacother 12:567-77. 2011
    ..In recent years, there has been great interest in the development of new oral anticoagulants with a more efficient pharmacological profile, first tested in venous thromboembolism prevention and later in AF...
  6. doi request reprint Pharmacogenomics and adverse drug reactions: the case of statins
    Mariano A Giorgi
    Department of Cardiology and Cardiovascular Surgery, Montañeses 2325 1428, FLENI, Buenos Aires, Argentina
    Expert Opin Pharmacother 12:1499-509. 2011
    ..Nevertheless, the clinical use of this information is far from known at present and needs to be evaluated...